Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 7/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | POLB | P06746 | 1/20 | 0.63 |
| ▸ | HTR1A | P08908 | 1/20 | 0.63 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.63 |
| ▸ | HTR6 | P50406 | 1/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13323539 | 0.83 | SLC6A4 (1.00) | SLC6A4KDM4ELMNAPOLBHTR1A | |
| SCHEMBL18324815 | 0.83 | SLC6A4 (0.71) | SLC6A4HTR1AHTR6 | |
| SCHEMBL16801569 | 0.83 | SLC6A4 (0.71) | SLC6A4HTR1AHTR6 | |
| SCHEMBL7325315 | 0.82 | SLC6A4 (0.69) | SLC6A4KDM4ELMNAPOLBHTR1A | |
| SCHEMBL6345407 | 0.81 | SLC6A4 (0.69) | SLC6A4HTR1AHTR6 | |
| SCHEMBL1275594 | 0.81 | SLC6A4 (1.00) | SLC6A4KDM4ELMNAPOLBHTR1A | |
| SCHEMBL7479356 | 0.81 | SLC6A4 (0.76) | SLC6A4KDM4ELMNAPOLBHTR1A | |
| SCHEMBL5367487 | 0.81 | SLC6A4 (0.76) | SLC6A4KDM4ELMNAPOLBHTR1A | |
| SCHEMBL4673448 | 0.81 | SLC6A4 (1.00) | SLC6A4KDM4ELMNAPOLBHTR1A | |
| SCHEMBL3130981 | 0.81 | SLC6A4 (1.00) | SLC6A4KDM4ELMNAPOLBHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140051687-A1 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON, INC. (CA) | 2014-02-20 | — | — | US | disclosed |
| US-20140051687-A1 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON, INC. (CA) | 2014-02-20 | — | — | US | disclosed |
| US-8586620-B2 | Substituted indole compounds having NOS inhibitory activity | NEURAXON, INC. (CA) | 2013-11-19 | — | — | US | disclosed |
| US-20110212947-A1 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON INC. (CA) | 2011-09-01 | — | — | US | disclosed |
| US-20110212947-A1 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON INC. (CA) | 2011-09-01 | — | — | US | disclosed |
| US-7951940-B2 | neuronal nitric oxide synthase (nNOS) isoform inhibitors; 2-ethyl-1-(1H-indol-5-yl)-isothiourea; neurogenerative disorders, stroke, reperfusion injury, head trauma, migraine headache, neuropathic pain, drug abuse, hyperalgesia | NEURAXON, INC. (CA) | 2011-05-31 | — | — | US | disclosed |
| US-7951940-B2 | neuronal nitric oxide synthase (nNOS) isoform inhibitors; 2-ethyl-1-(1H-indol-5-yl)-isothiourea; neurogenerative disorders, stroke, reperfusion injury, head trauma, migraine headache, neuropathic pain, drug abuse, hyperalgesia | NEURAXON, INC. (CA) | 2011-05-31 | — | — | US | disclosed |
| EP-1883451-B9 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON INC (CA) | 2011-02-09 | — | — | EP | disclosed |
| EP-1883451-B1 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON INC (CA) | 2010-11-24 | — | — | EP | disclosed |
| US-20100152177-A1 | COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-06-17 | — | — | US | disclosed |
| EP-0812826-A1 | 1H-indole and benzo(b)thiophene derivatives with 4-(1,2,3,6-tetra:hydro:pyridinyl)- and 4-piperidinyl-groups bound to the heterocyclic ring as inhibitors of serotonin reuptake | ELI LILLY AND COMPANY (US) | 1997-12-17 | — | — | EP | disclosed |
| EP-0486666-B1 | THERAPEUTIC HETEROCYCLIC COMPOUNDS | ZENECA LTD (GB) | 1997-08-13 | — | — | EP | disclosed |
| EP-0571471-B1 | 5-HETEROYL INDOLE DERIVATIVES | PFIZER (US) | 1996-03-06 | — | — | EP | disclosed |
| US-5466699-A | Indolyl compounds for treating migraine | BURROUGHS WELLCOME CO. (US) | 1995-11-14 | — | — | US | disclosed |
| US-5409941-A | 5-heteroyl indole derivatives | PFIZER INC. (US) | 1995-04-25 | — | — | US | disclosed |
| US-5399574-A | 5-hydroxytryptamine agonists; vasoconstrictors | BURROUGHS WELLCOME CO. (US) | 1995-03-21 | — | — | US | disclosed |
| EP-0636623-A1 | Indole derivatives as 5-HT1- like agonists | THE WELLCOME FOUNDATION LIMITED (GB) | 1995-02-01 | — | — | EP | disclosed |
| WO-1992013856-A1 | 5-HETEROYL INDOLE DERIVATIVES | PFIZER INC. (US) | 1992-08-20 | — | — | WO | disclosed |
| EP-0486666-A1 | THERAPEUTIC HETEROCYCLIC COMPOUNDS. | WELLCOME FOUND (GB) | 1992-05-27 | — | — | EP | disclosed |
| WO-1991018897-A1 | THERAPEUTIC HETEROCYCLIC COMPOUNDS | THE WELLCOME FOUNDATION LIMITED (GB) | 1991-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212947-A1 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NOS2, NOS1, NOS3 | SLC6A4 215/4885KDM4E 2379/4885LMNA 3365/4885 |
| US-20100152177-A1 | COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | HTR6, HTR3B, HTR1B | SLC6A4 21/4885KDM4E 2197/4885LMNA 2331/4885 |
| US-20140051687-A1 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NOS2, NOS1, NOS3 | SLC6A4 215/4885KDM4E 2379/4885LMNA 3365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.